Linked Color Imaging Based CMV Diagnosis for Gastric Mucosal Lesions
Primary Purpose
Gastric Disease
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
WLE and then LCI
LCI and then WLE
Sponsored by
About this trial
This is an interventional diagnostic trial for Gastric Disease
Eligibility Criteria
Inclusion Criteria:
- Above 18 years old patients
- Who agree to participate in the study
- Patients with the indications for gastroduodenoscopy
Exclusion Criteria:
- Patients, who were receiving nonsteroidal anti-inflammatory drugs, pump inhibitors (PPI) or antibiotics in the last 3 weeks.
- Severe uncontrolled coagulopathy
- Prior history of gastric surgery.
- Pregnancy and lactation
Sites / Locations
- Affiliated Hospital to Academy of Military Medical Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Group A
Group B
Arm Description
Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
Outcomes
Primary Outcome Measures
Diagnostic accuracy
Diagnostic accuracy of LCI for gastric diseases was calculated by comparing the LCI endoscopic diagnosis with pathological diagnosis.
Secondary Outcome Measures
Numbers of lesions in the stomach
The numbers of lesion detected under WLE and LCI will be recorded and compared.
Endoscopic examination duration
The time spent on the endoscopic examination using WLE and LCI will be compared.
Full Information
NCT ID
NCT03092414
First Posted
March 21, 2017
Last Updated
March 25, 2017
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT03092414
Brief Title
Linked Color Imaging Based CMV Diagnosis for Gastric Mucosal Lesions
Official Title
CMV Criteria in the Detection of Gastric Diseases Using Linked Color Imaging
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Unknown status
Study Start Date
May 2017 (Anticipated)
Primary Completion Date
July 2017 (Anticipated)
Study Completion Date
August 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The newly developed linked color imaging (LCI) system (FUJIFILM Co.) creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of BLI technology. This system can obtain bright endoscopic images even at a distant view because LCI has more intense white light than the short-wavelength narrow-band laser light. Short-wavelength narrow-band laser light enhances the vessels on the mucosal surface and the patterns of the mucosa. Therefore, LCI may facilitate the detection of gastric mucosal lesions. Further studies are needed to confirm the clinical utility of LCI.
Detailed Description
LCI enhances differences in hue, in the red region of the spectrum, through digital processing. This makes red areas appear redder and white areas appear whiter. Thus, it is easier to recognize a slight difference in color of the mucosa. Based on previous experience, a new LCI based endoscopic diagnosis criteria called CMV (color- microstructure-vessel) criteria has been proposed, which could be used for judging the gastric mucosal lesions. LCI has the advantage of detecting color changes of the mucosa, and this could provide very valuable and useful evidence for making endoscopic diagnosis. In this study, a blinded random controlled clinical trial is designed to further validate the diagnostic value of LCI based CMV criteria for gastric diseases.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Disease
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
2000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Experimental
Arm Description
Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
Arm Title
Group B
Arm Type
Experimental
Arm Description
Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
Intervention Type
Procedure
Intervention Name(s)
WLE and then LCI
Intervention Description
The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
Intervention Type
Procedure
Intervention Name(s)
LCI and then WLE
Intervention Description
The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
Primary Outcome Measure Information:
Title
Diagnostic accuracy
Description
Diagnostic accuracy of LCI for gastric diseases was calculated by comparing the LCI endoscopic diagnosis with pathological diagnosis.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Numbers of lesions in the stomach
Description
The numbers of lesion detected under WLE and LCI will be recorded and compared.
Time Frame
4 months
Title
Endoscopic examination duration
Description
The time spent on the endoscopic examination using WLE and LCI will be compared.
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Above 18 years old patients
Who agree to participate in the study
Patients with the indications for gastroduodenoscopy
Exclusion Criteria:
Patients, who were receiving nonsteroidal anti-inflammatory drugs, pump inhibitors (PPI) or antibiotics in the last 3 weeks.
Severe uncontrolled coagulopathy
Prior history of gastric surgery.
Pregnancy and lactation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaotian Sun, M.D., Ph.D.
Email
xiaotian-sun@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan Liu, M.D., Ph.D.
Organizational Affiliation
Affiliated Hospital to Academy of Military Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Affiliated Hospital to Academy of Military Medical Sciences
City
Beijing
ZIP/Postal Code
100071
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27641243
Citation
Sun X, Dong T, Bi Y, Min M, Shen W, Xu Y, Liu Y. Linked color imaging application for improving the endoscopic diagnosis accuracy: a pilot study. Sci Rep. 2016 Sep 19;6:33473. doi: 10.1038/srep33473.
Results Reference
background
PubMed Identifier
27556101
Citation
Dohi O, Yagi N, Onozawa Y, Kimura-Tsuchiya R, Majima A, Kitaichi T, Horii Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging improves endoscopic diagnosis of active Helicobacter pylori infection. Endosc Int Open. 2016 Jul;4(7):E800-5. doi: 10.1055/s-0042-109049.
Results Reference
background
PubMed Identifier
27770584
Citation
Ono S, Abiko S, Kato M. Linked color imaging enhances gastric cancer in gastric intestinal metaplasia. Dig Endosc. 2017 Mar;29(2):230-231. doi: 10.1111/den.12757. Epub 2016 Nov 21. No abstract available.
Results Reference
background
PubMed Identifier
30896610
Citation
Min M, Dong TH, Liu Y, Bi YL, Ma CY. Novel endoscopic findings as visualized by non-magnification endoscopy with linked color imaging are indicative of gastric intestinal metaplasia. Chin Med J (Engl). 2019 Apr 5;132(7):782-788. doi: 10.1097/CM9.0000000000000172.
Results Reference
derived
Learn more about this trial
Linked Color Imaging Based CMV Diagnosis for Gastric Mucosal Lesions
We'll reach out to this number within 24 hrs